title: Use, tolerability and compliance of spironolactone in the treatment of heart failure.
abstract: BACKGROUND
  Risk of morbidity and mortality in patients with severe heart failure (HF) is reduced by blockade of aldosterone receptors with spironolactone. However, benefits of spironolactone are potentially limited by treatment compliance and adverse events profile. The aim of this study was to estimate use of spironolactone by patients with HF, incidence of key adverse events, and patient compliance.
  
  
  METHODS
  This study was performed using data from the Quebec provincial medical and drug plans (Régie de l'Assurance Maladie du Québec, RAMQ) for patients who had a diagnosis of HF. Relative incidence of gynecomastia and hyperkalemia was estimated for users and non-users of spironolactone. Treatment adherence was estimated for users of spironolactone and compared to adherence with angiotensin converting enzyme (ACE) inhibitors, beta-blockers (β-blockers), and angiotensin receptor blockers (ARBs).
  
  
  RESULTS
  RAMQ data were obtained for a total of 82,018 patients with a diagnosis of HF. Of these patients, 59.9% used an ACE inhibitor, 59.5% used a beta-blocker, 28.4% used an ARB, and 15.1% (n = 12,344) used spironolactone. Despite underestimation due to limitation of the database, the documented incidence of hyperkalemia (3.3% versus 1.4%) and gynecomastia (1.8% versus 0.7%) was significantly higher in spironolactone users than non-users (p < 0.001). Treatment compliance was significantly lower with spironolactone compared to ACE inhibitors, β-blockers, and ARBs (45.6% versus 56.1%, 59.7%, and 57.0%, respectively; p < 0.001). Persistence to treatment over a one-year period was also lower with spironolactone compared to ACE inhibitors, β-blockers, and ARBs (50.7% versus 64.5%, 70.4%, and 66.3%, respectively; p < 0.001).
  
  
  CONCLUSIONS
  Use of spironolactone is associated with an incidence of adverse events, which may have an impact on treatment compliance.
authors: Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada. jean.lachaine@umontreal.ca
authors: Jean
authors: J
authors: Lachaine
authors: Catherine
authors: C
authors: Beauchemin
authors: Elodie
authors: E
authors: Ramos
references: N Engl J Med. 1999 Sep 2;341(10):753-5
references: 10471464
references: Congest Heart Fail. 2002 Jan-Feb;8(1):18-22
references: 11821624
references: Can J Cardiol. 2004 Oct;20(12):1205-11
references: 15494772
references: J Gastroenterol Hepatol. 2010 Feb;25(2):325-33
references: 20074146
references: N Engl J Med. 1999 Sep 2;341(10):709-17
references: 10471456
references: BMJ. 2003 Jul 19;327(7407):147-9
references: 12869459
references: Med J Aust. 2006 Nov 20;185(10):549-57
references: 17115967
references: Am J Cardiol. 1996 Oct 15;78(8):902-7
references: 8888663
references: Arch Intern Med. 2011 Feb 14;171(3):211-7
references: 20937918
references: Lancet. 1999 Apr 17;353(9161):1360-1
references: 10218555
references: Gastroenterology. 2007 Nov;133(5):1670-89
references: 17983810
references: Can J Cardiol. 2006 Jan;22(1):23-45
references: 16450016
references: Can J Cardiol. 2006 Jul;22(9):749-54
references: 16835668
references: N Engl J Med. 1991 Aug 1;325(5):293-302
references: 2057034
references: J Emerg Med. 2002 May;22(4):349-52
references: 12113843
references: Pharm World Sci. 2001 Aug;23(4):132-4
references: 11599198
references: Drugs. 1985 Jul;30(1):32-41
references: 2863124
references: J Clin Epidemiol. 1992 Feb;45(2):197-203
references: 1573438